William Nyberg

SciLifeLab Fellow, Karolinska Institutet

Key publications

Nyberg WA, Ark J, To A, Clouden S, Reeder G, Muldoon JJ, Chung JY, Xie WX, Allain V, Steinhart Z, Chang C, Talbot A, Kim S, Rosales A, Havlik LP, Pimentel H, Asokan A, Eyquem J.
An evolved AAV variant enables efficient genetic engineering of murine T cells.
Cell, 186(2), 446-460.e19 (2023).

Carnevale J, Shifrut E, Kale N, Nyberg WA, Blaeschke F, Chen YY, Li Z, Bapat SP, Diolaiti ME, O’Leary P, Vedova S, Belk J, Daniel B, Roth TL, Bachl S, Anido AA, Prinzing B, Ibañez-Vega J, Lange S, Haydar D, Luetke-Eversloh M, Born-Bony M, Hegde B, Kogan S, Feuchtinger T, Okada H, Satpathy AT, Shannon K, Gottschalk S, Eyquem J, Krenciute G, Ashworth A, Marson A.
RASA2 ablation in T cells boosts antigen sensitivity and long-term function.
Nature, 609(7925), 174-182 (2022).

Blaeschke F, Chen YY, Apathy R, Daniel B, Chen AY, Chen PA, Sandor K, Zhang W, Li Z, Mowery CT, Yamamoto TN, Nyberg WA, To A, Yu R, Bueno R, Kim MC, Schmidt R, Goodman DB, Feuchtinger T, Eyquem J, Jimmie Ye C, Carnevale J, Satpathy AT, Shifrut E, Roth TL, Marson A.
Modular pooled discovery of synthetic knockin sequences to program durable cell therapies.
Cell, 186(19), 4216-4234.e33 (2023).

Nyberg WA, Eyquem J.
Genome Editing Applications in Cancer T Cell Therapy.
Genome Editing in Drug Discovery, Chapter 16, 213-259, ISBN: 9781119671404 (2022).

Nyberg Lab

Our lab focuses on reprogramming T cells using advanced genetical engineering for therapeutic purposes. This is done primarily with the use of chimeric antigen receptors (CAR), but we are also exploring the use of other synthetic receptors and therapeutic TCR sequences to develop new T cell therapies against cancers. The lab uses cutting-edge technologies for precise genome engineering and large-scale genetic screens to enhance the therapeutic potential of T cells.

One of the main research lines in the lab is to develop and enhance in situ engineering of T cells. Current manufacturing processes for cell therapies requires ex vivo manufacturing of cell products, which significantly limit the access and possibilities of cell therapies and is associated with large costs. In the Nyberg lab we are working on solutions to engineer T cells directly in patients to re-program them for therapeutic purposes, this is done primarily with the use of engineered viral vectors and synthetic delivery vehicles packaged with CRISPR/Cas9 components and DNA templates.  We develop these technologies and validate their functionality in vivo with the use humanized mouse models as well as primary human immune cells for in vitro studies.

Another reasearch focus in the lab is to enhance the use of CAR-T cells in solid tumor cancers. One of the major issue with CAR-T cell therapies in solid tumor cancers is T cell exhaustion and dysfucntion caused by immunosuppressive tumor microenvironements. To do this we work primarily with immunocompetent mouse models which we use to screen for new synthetic receptors and co-stimulatory factors with large DNA libraries that can help improve CAR-T cell fitness in immunosuppressive tumor microenvironments.

The Nyberg lab is actively recruiting ambitious and talented postdocs, PhD candidates and master students that are interested in our research.

Group members

Julian Fischbach

Last updated: 2024-08-12

Content Responsible: Hampus Persson(hampus.persson@scilifelab.uu.se)